The Next Leap in Dyslipidemia Management
Staten Biotechnology aims to develop novel and innovative strategies for the prevention of cardiovascular events, the largest unmet medical need in dyslipidemia. Dyslipidemia is an abnormal amount of lipids or fat in the blood, namely triglycerides, cholesterol, or fat phospholipids. In developed countries most dyslipidemias are hyperlipidemia, i.e. elevation of lipids in the blood, and can be caused by genetic factors, diet, and lifestyle.
Staten is developing a human monoclonal antibody with a unique approach towards neutralizing apoC3 – a key molecule in dyslipidemia management – which reduces triglyceride levels and increases removal of atherogenic lipoprotein remnant particles. Reduction of these lipids in the blood is known to have a positive impact in vascular and heart diseases. With this monoclonal antibody Staten is leading the next step in dyslipidemia management.